Ann: Appointment of Non-Executive Director and Appendix 3X, page-6

I should add i do feel the effort to get some deals with fpp tech does make the most sense. At the same time it is incredibly frustrating to follow announcements that we are turning into an oncology company targetting myc. Then we have multiple myc inhibitors better than omomyc. Then we are doing heaps of research to choose best candidate. Then we are creating data packs thst are eagerly awaited by pharma, then we are still creating data packs that are eagerly awaited and imyc looks even better, then......Yeah nah forget that, whole thing shelved with no information on current point of progress after we funded it all with last cr. For the first time in a long while I am starting to question where we are going due to t he fact we have had endosomal escape for years now with no related deal...what is different right now??